Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | RBP4 | P02753 | 12/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1818094 | 0.84 | CYP3A4 (0.36) | CYP3A4CYP2C9GAAL3MBTL1 | |
| SCHEMBL1814676 | 0.83 | CYP3A4 (0.46) | CYP3A4CYP2C9HTT | |
| SCHEMBL6061289 | 0.80 | CYP3A4 (0.33) | CYP3A4CYP2C9GBA1GAAL3MBTL1 | |
| SCHEMBL1814419 | 0.79 | CYP3A4 (0.35) | CYP3A4CYP2C9 | |
| SCHEMBL5634126 | 0.79 | CYP3A4 (0.40) | CYP3A4CYP2C9RBP4PIM1TDP1 | |
| SCHEMBL4885373 | 0.75 | CYP3A4 (0.36) | CYP3A4CYP2C9 | |
| SCHEMBL4887936 | 0.75 | CYP3A4 (0.34) | CYP3A4CYP2C9 | |
| SCHEMBL1812017 | 0.67 | CYP3A4 (0.35) | CYP3A4CYP2C9 | |
| SCHEMBL14685313 | 0.66 | ATP4A (0.48) | CYP3A4CYP2C9GAA | |
| SCHEMBL1219275 | 0.66 | CYP3A4 (0.38) | CYP3A4CYP2C9GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0971922-B1 | TETRAHYDROPYRIDO COMPOUNDS | ALTANA PHARMA AG (DE) | 2004-04-28 | — | — | EP | claimed |
| US-6197783-B1 | THERAPY FOR GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-03-06 | — | — | US | claimed |
| US-7951398-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | NYCOMED GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20090048287-A1 | Compositions useful for treating gastrointestinal motility disorders | EDUSA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20070122474-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG | 2007-05-31 | — | — | US | disclosed |
| US-7196196-B2 | Substituted imidazo[1, 2-a]-5,6,7,8-tetrahydropyridine-8-ones, method for their production and the use thereof for producing imidazo[1,2-a]pyridines | BASF AKTIENGESELLSCHAFT (DE) | 2007-03-27 | — | — | US | disclosed |
| US-7175854-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060189648-A1 | Compositions useful for increasing lower esophageal sphincter pressure | EDUSA PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1663313-A2 | COMPOSITIONS USEFUL FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | Dynogen Pharmaceuticals Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050059704-A1 | Compositions useful for treating gastrointestinal motility disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005021040-A2 | COMPOSITIONS USEFUL FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050020620-A1 | Substituted imidazo[1, 2-a]-5,6,7,8-tetrahydropyridine-8-ones, method for their production and the use thereof for producing imidazo[1,2-a]pyridines | BASF AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | disclosed |
| EP-0971922-B1 | TETRAHYDROPYRIDO COMPOUNDS | ALTANA PHARMA AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20040058896-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| US-6197783-B1 | THERAPY FOR GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048287-A1 | Compositions useful for treating gastrointestinal motility disorders | HRH2, MLNR, HTR3A | CYP3A4 1306/4885CYP2C9 1083/4885RBP4 3603/4885 |
| US-20050059704-A1 | Compositions useful for treating gastrointestinal motility disorders | HRH2, MLNR, HTR3A | CYP3A4 1306/4885CYP2C9 1083/4885RBP4 3603/4885 |
| US-20060189648-A1 | Compositions useful for increasing lower esophageal sphincter pressure | HTR3A, HTR3D, HTR3B | CYP3A4 2764/4885CYP2C9 2333/4885RBP4 1379/4885 |
| US-20050020620-A1 | Substituted imidazo[1, 2-a]-5,6,7,8-tetrahydropyridine-8-ones, method for their production and the use thereof for producing imidazo[1,2-a]pyridines | BTN3A1, DHPS, NISCH | CYP3A4 48/4885CYP2C9 249/4885RBP4 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.